

List of Abbreviations

Abbreviations	Full Form
AD	Alzheimer's disease
ATP	Adenosine triphosphate
ADP	Adenosine diphosphate
ADME	Absorption, Distribution, Metabolism, and Excretion
ADT	Agar Diffusion Test
BBB	Blood-Brain Barrier
CHCl ₃	Chloroform
CDCl ₃	Deuterated Chloroform
CC ₅₀	Cytotoxic concentration required to kill 50% of the population
DL	Druglikeness
DCCD	N, N-Dicyclohexylcarbodiimide
DMF	Dimethylformamide
DCM	Dichloromethane
DMSO	Dimethyl sulfoxide
EPS	Extrapyramidal side-effects
EMEM	Eagle's Minimal Essential Medium
Et ₂ O	Diethyl ether
Et ₃ N	Triethylamine
FZ	Flumazinil
HTS	High Throughput Screening
HIV	Human Immunodeficiency Virus
HBA	Hydrogen Bond Acceptor
HBD	Hydrogen Bond Donor
HQNO	2-heptyl-4-hydroxyquinoline-N-oxide
IC ₅₀	Inhibitory concentration required to kill 50% of the population
IMVs	Inverted Membrane Vesicles
K ₂ CO ₃	Potassium carbonate

KH ₂ PO ₄	Potassium dihydrogen phosphate
KOH	Potassium hydroxide
KI	Potassium iodide
MTT	3-(4,5-dimethyl-2-thiazolyl)-2,5-diphenyl-tetrazolium bromide
MeOH	Methanol
MgCl ₂	Magnesium chloride
NMR	Nuclear Magnetic Resonance
NaCl	Sodium chloride
ODCB	1-2-dichlorobenzene
PMF	Proton Motive Force
PAMPA	Parallel Artificial Membrane Permeability Assay
PDB	Protein Data Bank
PBL	Porcine Brain Lipid
Pe	Permeability
RMSD	Root Mean Square Deviation
SI	Selectivity Index
SAR	Structure-activity relationship
SEM	Standard Error of the Mean
TGI	Total Growth Inhibition
TLC	Thin-Layer Chromatography
TSA	Total Surface Area
TPSA	Topological Polar Surface Area
THF	Tetrahydrofuran
US-FDA	United States- Food and Drug Administration
UV	Ultraviolet
WHO	World Health Organization
3D	Three-Dimensional
5-HT	5-hydroxytryptamine

List of Symbols

Symbols	Meaning
α	Alpha
β	Beta
δ	Delta
ε	Epsilon
$^{\circ}\text{C}$	Degree Celsius
\AA	Angstrom
©	Copyright
g	Gram; Gravitational force
mg	Milligram
μg	Micro gram
ng	Nano gram
μM	Micro Mole
mmol	Milli Mole
mL	Milliliter
μL	Microliter
mV	Millivolt
h	Hour
s	Second; Singlet
nm	Nanometer
μm	Micrometer
mm	Millimeter
cm	Centimeter
ppm	Parts per million
rpm	Revolutions per minute
Kcal	Kilocalories
Hz	Hertz
MHz	Megahertz
J	Coupling constant
d	Doublet
m	Multiplet
dd	Doublet of doublet

m/z	Mass to charge ratio
%	Percent
pH	Potential of hydrogen
\leq	Less than or equal
<	Less than
>	More than
\pm	Plus or minus

List of Tables

Table No.	Description	Page No.
1.1	Various pathological factors involved in AD	8
2.1	γ -Secretase inhibitors for AD	22
2.2	γ -Secretase inhibitors for AD	25
2.3	Piperidine N-arylsulfonamide derivatives with IC ₅₀ and CYP 3A4 inhibition activity.	27
2.4	Natural products effective in AD therapy along with their mode of action.	42
2.5	GSK-3 and tau-based investigational drugs in clinical development	60
2.6	Biomarkers in the treatment of AD	75
2.7	Repurposing drugs in clinical trail	78
4.1	Aromatic and aliphatic piperazine derivatives with inhibitory activities (IC ₅₀) against AChE and MMP-2.	113
4.2	Measurement of initial velocity of enzyme as a function of substrate concentration at an inhibitor concentrations of 0, 60 nM and 100 nM	118
4.3	Permeability (Pe \times 10 ⁻⁶ cm/s) of the 9 commercial drugs to validate the PAMPA-BBB model	119
4.4	Permeability, Pe (10 ⁻⁶ cm s ⁻¹) determined by BBB-PAMPA study and DPPH based free radical scavenging activity of synthesized compounds	121
4.5	LD ₅₀ determination protocol for compound 52.	127
4.6	Effect of compound 52 on body wt. of animals at dose of 300 mg/kg.	127
4.7	Onset of toxicity with compound 52 in 72h.	128
4.8	LD ₅₀ determination protocol for compound 46	128
4.9	Effect of compound 46 on body wt. of animals at dose of 300 mg/kg.	128
4.10	Onset of toxicity with compound 46 in 72h	128
5.1	Behavioral effect, on OFT, of compounds 52, 53 and 55	144

5.2	Pharmacological effects of compounds 52, 53 and 55 on levels of monoamines, their metabolites and ratio in amygdala.	148
5.3	Flumazenil (FZ) antagonism on activity of diazepam and compound 52 in OFT experiment at dose of 1mg/kg	149
6.1	Distance between pharmacophoric features in Å	198
6.2	Drug-likeness, ADME and toxicity prediction of the compounds.	200
6.3	Adamantyl (scheme I) and 1,4-disubstituted 1,2,3-triazoles (scheme II) analogues with inhibitory activities (IC ₅₀) viz. MMP-2, Aβ ₁₋₄₂ % aggregation, EC ₅₀ of DPPH assay, and neuroprotection assay against MC65 cell line showing cell viability	205
7.1	Binding energy of compound against AChE (PDB id 4EY7), BuChE (PDB id 4BDS), and BACE-1 (PDB id 6EQM).	264
7.2	Quinolinyl alkyl piperazine (scheme I) analogues with inhibitory activities (IC ₅₀) AChE, BuChE and BACE-1 assay ±SE.	268
7.3	Quinolinyl piperazine alkyl (scheme II) analogues with inhibitory activities (IC ₅₀) AChE, BuChE and BACE-1 assay ±SE	269
7.4	4 Permeability, Pe (10 ⁻⁶ cm s ⁻¹) determined by BBB-PAMPA study	270
7.5	Pharmacokinetic studies of compounds 76 and 95; concentration of compound in plasma, brain and hippocampus after 30 min of dosing	271

List of figures

Figure No.	Description	Page No.
1.1	Clearance pathway of A β in normal brain	6
1.2	Various pathophysiological pathways of Alzheimer's disease	10
1.3	FDA approved AChE inhibitors for Alzheimer's disease	13
1.4	Structure of Memantine	13
2.1	γ -secretase cleavage site and catalytic core	18
2.2	Modification of 2,4,6-trisubstituted N-arylsulfonyl piperidines to find the agreement between CYP3A4 interaction and γ -secretase inhibition	26
2.3	Binding of GSMs at luminal side of PS induces a conformational change in the catalytic center of γ -secretase to modulate A β production.	29
2.4	γ - secretase inhibitors and modulators. (A). NSAID derived carboxylic acid analogs (B) Non-NSAID GSMs. (C) Natural products as potent GSMs. Structures of GSM-derived photoaffinity probes containing (D) biotin (E) alkyne.	32
2.5	Development of Non-NSAID GSMs.	37
2.6	Inhibitors and enhancers (A) Secretase inhibitors and enhancers (B) SIRT2 inhibitors (C) Caspases inhibitors.	47
2.7	Roles of SIRT in AD-related neurodegeneration	50
2.8	Structure of SIRT2; pink colored spheres show the atom	51
2.9	(A) Tacrine derivatives (31-34); Donepezil, Rivastigmine derivatives (35-38), (B) Metal chelators used in AD.	65
4.1	Design of multitarget-directed potential drug candidates for AD	110
4.2	Michaelis-Menten plot at seven different concentrations of substrate (20-70 nM) on three different concentrations of compound 46	116
4.3	Lineweaver-Burk plot on three different concentrations of	116

	compound 46 for AChE	
4.4	Dixon plot of compound 46 showing K_i value as negative intercept on X-axis of the Dixon plot for AChE.	117
4.5	Lineweaver-Burk plot on three different concentrations of compound 46 for MMP-2 enzyme	117
4.6	Determination of K_i against MMP-2 of compound 46	118
4.7	The secondary plot of K_m as a function of inhibitor concentration [I] for a competitive inhibitor (Compound 52)	118
4.8	The Linear correlation between reported and observed P_e of the commercial drugs by PAMPA assay.	120
4.9	MC65 neuroprotection with compound 46	122
4.10	Effect of DNP, compounds 52 and 46 on AChE induced $A\beta$ aggregation	123
4.11	Docking poses of compound 52 (a, c) and 46 (b,d) against $A\beta$ (PDB: 2LMN).	124
4.12	The metal chelating property of compound 46: The shift in UV spectra indicated the metal chelating property.	125
4.13	(A) FTIR spectra of the metal complex and compound 46 showing the shift in the bands. (B) UV-visible spectra of metal alone (C) UV spectra of buffer.	126
4.14	Effect of compounds 52, 46 and scopolamine on Spontaneous alternation score	130
4.15	Effect of scopolamine induced alteration in the passive avoidance Test	131
4.16	Effect of Scopolamine induced amnesia on mitochondrial membrane potential of brain isolated from animals used in the experiment	132
4.17	Neurochemical level estimation	133
5.1	Piperazinediones 52, 53 and 55 selected for anxiolytic activity	136
5.2	Elevated plus-maze: two-way ANOVA applied to demonstrate the results.	141
5.3	Evaluation of compounds 52, 53 and 55 on hole board	145

	experiment	
5.4	Flumazenil (FZ) antagonism on the activity of diazepam and compound 52	146
5.5	Flumazenil (FZ) antagonism on the activity of diazepam and compound 52	147
5.6	Effect of diazepam (6 mg/kg, p.o.) and compound 52 (6 mg/kg; p.o.) on ambulation	149
6.1	Paul von Ragué Schleyer method of adamantane synthesis	154
6.2	Conversion of adamantane to amantadine	155
6.3	1,2,3 and 1,2,4-triazoles in different tautomeric forms	155
6.4	Synthesis of 4-formyl-1-phenyl- <i>v</i> -triazole	155
6.5	Mechanism of copper catalyzed selective synthesis of 1,2,3-triazoles.	156
6.6	Drug design strategy of NMDA series	157
6.7	Method of identification of activity against different subtypes of NMDA	197
6.8	Pharmacophoric features of Ifenprodil used for screening	198
6.9	Ramachandran plot for modeled protein	201
6.10	Docking pose of compound 22	201
6.11	Docking pose of compound 24	202
6.12	Docking pose of compound 26	202
6.13	Inhibition assay of metal induced A β ₁₋₄₂ aggregation and its confocal imaging	206
6.14	Effect of Compounds 22, 24, 26 on Glycine and glutamate evoked currents in GluN1/GluN2A containing receptor and GluN1A/GluN2B containing receptor	209
6.15	Inhibition of current induced by 100 μ M glutamate and 10 μ M glycine in presence of antagonists tested on GluN1A/GluN2B containing receptor	210
6.16	(A) and (B) Protein RMSD and Protein Ligand RMSD respectively. (C) Root Mean Square Fluctuation (RMSF) of protein in presence of compound. (D) RMSF of ligand (E) Interaction fraction of Protein-Ligand Contacts (F) Protein	210

	ligand interaction.	
7.1	Doebner's reaction for the synthesis of quinoline-4-carboxylic acids	213
7.2	Skraup method of synthesis for quinoline	214
7.3	Drug design strategy for the development of AChE and BACE inhibitor.	214
7.4	Docking pose of compound 97 with (A) AChE (PDB id 4EY7), (B) BuChE (PDB id 4BDS) and (C) BACE-1 (PDB id 6EQM).	265
7.5	Neuroprotection assay of compound 95 on MC 65 cell line	272

Preface

Alzheimer's Disease (AD) is most common neurodegenerative disorder, which accounts for more than 80% of dementia cases worldwide in older people. It is characterized by deposition of amyloid β and neuro-fibrillary tangles. The disease leads to progressive loss of memory, functional ability to learn and is primarily characterized by the progressive loss of memory associated with other cognitive deficits. The global burden on the population suffering from AD was assessed to 44 million in 2015. This number is expected to double by 2030 and triple by 2050, if no effective treatment is in place. In a country like India, where approximately 41 % of the population is in the age group of 25 to 55 years, this needs to be seriously acknowledged and addressed.

Over the last few years, several targets of the disease have been identified. This include, but not limited to, Amyloid- β , Acetylcholinesterase (AChE), Butyrylcholinesterase (BuChE), β -secretase, γ -secretase, β -site APP cleaving enzyme-1 (BACE-1), NMDA receptors, Matrix metalloproteinases (MMPs), Neurofibrillary tangles *etc.*

Despite decades of study on the etiology of disease and also significant efforts by pharmaceutical industry to develop therapies, there is no effective treatment available to cure AD or to inhibit significantly its progression. However, there are four drugs viz. donepezil, galantamine, and rivastigmine, approved by USFDA, acting on cholinergic pathway and recently (2003) approved drug Memantine acting on NMDA receptor.

Considering the complex and multifactorial nature of disease, development of multifunctional ligands was considered a better option.

The present study is being divided into eight chapters. Chapter 1 deals with different types of neurodegenerative disorders, pathophysiology of AD and available treatments.

Chapter 2 provides insight in the literature reports related to the work from scholarly articles which forms the basis of the study. The section summarizes drugable targets for the treatment of AD and agonists or antagonists developed in the recent times. The mechanism of action of inhibitors and the molecular features of the receptors are also discussed in detail. The structural requirements for the agonistic or antagonistic action are explained along with structure-activity relationship (SAR) of the molecules. Chapter 3 includes the hypothesis of the study, and rationale of the work. It also incorporates the plan of study that helped to accomplish the research envisaged.

Chapter 4 deals with the rationale for syntheses of novel piperazinediones, obtained from *in-silico* studies and data mining. The development of pharmacophore was based on the hybrid drug design considering donepezil and PQ912, a chemical moiety in phase II of clinical trial. The designed hybrid pharmacophore was used for extensive data mining by using zinc and asinex databank which yielded over thousand compounds having desired pharmacophoric pattern. These data were further subjected to different filters viz. docking, *in-silico* BBB permeability and finally toxicity filter. The fully optimized molecules thus obtained were promoted to synthesis, *in-vitro* enzyme assays and *in-vivo* studies.. The potent molecules obtained from *in-vitro* study were further investigated for neuroprotection ability in MC 65 cells and antioxidant assay. Most potent compounds were selected for *in-vivo* studies in AD animal models to evaluate the working memory and learning response.

A few, piperazinediones developed also showed anxiolytic property which was further assessed and constitute chapter 5 *i.e.* biological profiling of piperazinediones for the management of anxiety associated with AD. In this, behavioral study on animal model was performed which was followed by estimation of neurotransmitter level in brain.

The detailed mode of action of compounds was also assessed by Flumazenil antagonism on anxiolytic activity of compound.

In the next chapter (Chapter 6), synthesis of adamantyl analogues as NMDA antagonists is included. Memantine, an approved NMDA antagonist, was retained in the final structure and further optimization was done using the fragments of hits obtained from virtual screening. Triazole moiety, reported to exhibit neuroprotective effect was incorporated in some of the compounds. The synthesized compounds were subjected to *in-vitro* MMP-2 inhibition assay, inhibition assay of metal-induced A β ₁₋₄₂ aggregation, confocal fluorescence imaging, antioxidant activity (DPPH assay), MC65 neuroprotection assay, and electrophysiology on different glutamate and glycine-mediated NMDA receptors and results were analyzed.

Another series of novel compounds synthesized, are presented in chapter 7. This includes quinoline analogues as potent inhibitors of AChE, BuChE, and BACE-1. Fragments from different bioactive molecules *viz* donepezil, LY2811376, MK-8631 were taken and docked against AChE, BACE1. These fragments were further developed by fragment-based techniques. Quinolines, found to be active against AChE and A β ₁₋₄₂ in our earlier study and piperazines, reported in many CNS active drugs were used as fragments. The latter is also reported to improve the water solubility of small synthetic molecules without altering its BBB permeability. Linkers, substituted cyclohexane-1-amine or substituted benzyl-1-amine towards different amino acid residues were used to increase the approach of the tail group. The synthesized compounds were screened for *in-vitro* AChE, and BuChE inhibition, BACE1 inhibition, neuroprotection on MC65 cell lines, PAMPA assay, and pharmacokinetic studies on male Wistar rats.

The summary and conclusions of the study are included in chapter 8, which is followed by appendix and references.